Clinical Trials on Contact Dermatitis in Chile

Total 17 results

Pontificia Universidad Catolica de Chile

Completed

Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis (VIDATOPIC)

Atopic Dermatitis

Chile
Pontificia Universidad Catolica de Chile
University of Chile; Comisión Nacional de Investigación Científica y Tecnológica

Completed

Early Origins of Allergy and Asthma (ARIES)

Asthma | Allergy | Atopic Dermatitis | Food Allergy | Allergic Sensitisation

Chile
Pontificia Universidad Catolica de Chile
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile; Agencia Nacional...

Recruiting

Airborne Preventive Measures to Reduce New TB Infections in Household Contacts (TBMask)

Tuberculosis | Tuberculosis, Pulmonary | Household Contacts

Chile
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

United States, Chile, Canada, United Kingdom
University of Chile

Completed

Autologous Serum Efficacy Study in Patients With Severe Dry Eye

Dry Eye

Chile
Northwestern University

Completed

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

Psoriasis | Atopic Dermatitis

Chile, United States, Netherlands, Canada, Hong Kong, Italy
Sanofi

Completed

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

Netherlands, Chile, United States, Canada, Czechia, Germany, Poland
Pontificia Universidad Catolica de Chile
Hospital Dr Sotero del Rio

Unknown

Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye

Dry Eye | Keratoconjunctivitis Sicca | Lacrimal Apparatus Diseases | Conjunctival Diseases | Keratitis | Corneal Diseases | Sjogren's Syndrome

Chile
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)

Dermatitis Atopic

Japan, Chile, Canada, United States
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)

Dermatitis Atopic

Israel, Chile, Australia, United States, Canada, Korea, Republic of
Sanofi

Recruiting

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)

Dermatitis Atopic

Italy, United Kingdom, Argentina, France, Chile, Czechia, Germany, Japan, Spain, China, Netherlands, Brazil, Canada, Denmark, Korea, Republic of, South Africa, Taiwan, Poland, India
Pfizer

Completed

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Atopic Dermatitis

Spain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy
Amgen

Recruiting

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

Atopic Dermatitis

United States, Korea, Republic of, Taiwan, Spain, Croatia, China, Greece, Belgium, Thailand, Puerto Rico, Hungary, Poland, Germany, Brazil, Italy, Japan, Canada, France, Romania, Chile
Pfizer

Active, not recruiting

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

Dermatitis, Atopic

China, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more
Sanofi
Regeneron Pharmaceuticals

Completed

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

Neurodermatitis

United States, Canada, Chile, France, Hungary, Italy, Korea, Republic of, Portugal, Spain, Taiwan, United Kingdom
Pfizer

Completed

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

United States, Spain, Taiwan, Germany, Canada, China, Poland, Belgium, Serbia, Brazil, Russian Federation, Israel, Latvia, Italy, Romania, Mexico, Argentina, Bulgaria, Chile, Netherlands, Slovakia
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

Spain, Taiwan, United States, Australia, Poland, Germany, Hungary, Bulgaria, Czechia, Japan, Korea, Republic of, Latvia, Canada, United Kingdom, Mexico, Chile, Slovakia, Italy

Clinical Trials on Contact Dermatitis in Chile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations